



**Collectis S.A. announces participation in the SmallCap Event
On April 21st and 22nd in Paris, 'hotel Hilton Suffren' in Paris**

Biocitech Park, Romainville, April 10th 2008 – Collectis S.A. (Alternext: ALCLS), the biotech company developing meganucleases (a new range of genome engineering products for the healthcare, research and industrial sectors), today announced that it will participate in the SmallCap Event, a forum dedicated to meetings between institutional investors and listed companies from the Euronext Zone, on Monday 21st and Tuesday 22nd of April in Paris, Hotel Hilton, 18 Avenue de Suffren, Paris.

During these two days, André Choulika, founder and CEO, and Marc le Bozec, CFO, will meet with institutional investors to present Collectis and its development strategy.

The upcoming conferences Collectis will attend:

- **BioEquity Europe in Amsterdam** on May 28 and 29 2008,

Marc Le Bozec will participate in the Workshop entitled "listing for growth" with NYSE Euronext

- **BIO in San Diego** (US) from June 17 to 21 2008.



About Collectis

Collectis SA (www.collectis.com) is a world-leading company in genome engineering and genome surgery. The company is focused on developing and producing custom meganucleases for *in vivo* DNA surgery and also provides new tools for rational reverse genetics and targeted recombination. Collectis' products induce unique, site-directed, double-strand DNA breaks in living cells and can be used in a wide range of biotechnological and therapeutic applications.

A strong patent portfolio

Collectis holds a 148 patent and patent application portfolio, providing the company with a strong position in the field of homologous recombination (3 issued US patents) and meganucleases and uses thereof (18 issued US patents), both naturally-occurring and with engineered specificity. A significant part of this portfolio has been exclusively licensed by Institut Pasteur, which spun off the company in 2000.

Institut Pasteur has a long history in exploiting methods of homologous recombination with groups pioneering the field - a major scientific breakthrough (Nobel Prize 2007) and is today the assignee of cornerstone patents from the late 1980s in this field. The group which discovered meganucleases and published founding works on the I-SceI homing endonucleases (leading to the constitution of Collectis proprietary patent portfolio) is from Institut Pasteur.

A strong scientific background

Research groups involved in the discovery of meganucleases at Institut Pasteur and Collectis have published tens of founding publications in prestigious peer-review papers such as *Cell*, *Nature*, *Science*, *PNAS*, *JBC* and *JMB*. In 2007 alone, Collectis published 5 important scientific publications in peer-review journals, with a further 2 papers since the beginning of 2008.

A technology that delivers

Collectis currently holds an incremental pipeline of 18 meganucleases with modified specificity (derived from the I-CreI meganuclease), with applications in:

- Therapeutics - major indications are severe inborn genetic diseases, DNA virus infections, transplantation and cancer.
- Agricultural biotechnology - the major targets are crop improvement, biofuels and biofibers.
- Biomanufacturing - the major indications are cell line and recombinant protein improvement.
- BioTools - the major indication is research kit development for pharmacogenomic studies in general and drug screening in particular.

A partner-oriented strategy

The company has formed 48 industrial partnerships with pharmaceutical companies (Astra-Zeneca, GSK, Shire), agricultural biotechnology groups (Limagrain, Bayer, BASF, DuPont-Pioneer HiBred) and healthcare-focused biotech firms (Genentech, Trans Genic, Lexicon). Collectis contributes to over 20 academic partnerships, including those with the Institut Gustave Roussy cancer research centre, the Paris Children's Hospital (France), Children's Hospital Boston and the Harvard Gene Therapy Initiative (USA).

Financing

The company raised over €24m in an IPO on NYSE-Euronext Alternext (in February 2007), in order to increase its annual meganuclease production capacity to 20 by the end of 2008. To date, the company has raised over €40m in both private and public rounds of financing.

Collectis is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For more information on Collectis, visit our web site: www.collectis.com.



Practical information:

ISIN Code FR0010425595

Ticker code ALCLS

Collectis' Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements concerning Collectis SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Collectis SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Collectis SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Collectis SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the prospectus approved by the French Autorité des Marchés Financiers ("AMF") on January 22nd, 2007 under visa number 07-023, available on the websites of the AMF (<http://www.amf-france.org>) and Collectis (<http://www.collectis.com>).

For additional information, please contact:

Collectis S.A.

Marc Le Bozec, CFO
+33 (0)1 41 83 99 00
investors@collectis.com

Alize RP

Caroline Carmagnol
+33 (0)6 64 18 99 59
caroline@alizerp.com